Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis.
Amani M CobertCatherine HelmsChris LarckDonald C MoorePublished in: Therapeutic advances in drug safety (2020)
Our meta-analysis demonstrates that T-DM1-based therapy is associated with an increased risk of AST and ALT elevations.